Atopic Dermatitis Summit: Perspectives on a Global Burden of Disease
The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control. There are several new targeted therapeutics with novel mechanisms of action, as well as existing therapies being investigated for treatment in additional age indications, being added to the treatment toolkit for moderate-to-severe atopic dermatitis around the globe, including but not limited to the United States, Canada, European Union, Japan, and China. It is imperative that clinicians are aware of the need for these newer targeted therapies, how to prescribe them appropriately for optimized treatment regimens and patient outcomes, and how to address any region-specific challenges with patient care.
Target Audience
This educational activity is designed for a global audience of physicians, nurses, pharmacists, and other allied health providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.
Learning Objectives
- Review clinical features of moderate-to-severe atopic dermatitis
- Identify tools for assessing atopic dermatitis severity
- Summarize the efficacy and safety of current and emerging targeted therapies for treatment of moderate-to-severe AD
- Discuss individualized treatment plans for pediatric and adult patients with moderate-to-severe AD that promote long-term disease management and improved quality of life
- Recognize strategies for patient-clinician communication that will aid shared decision making in the treatment of AD
- AD Across the Globe: North America
- AD Across the Globe: Europe and the
- AD Across the Globe: Japan and China
- Interactive Panel Discussion
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and LiVDerm. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Term Offering
This activity was released on March 31, 2023 and is valid for one year. Requests for credit must be made no later than March 31, 2024.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the activity in person, complete the posttest with 70% or better, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is $0 fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter | Reported Financial Relationship |
Prof. Thomas Bieber, MD, PhD, MDRA, Prof. h.c | Consulting Fee (e.g., Advisory Board): AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L´Oréal, MSD, Medac, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB, Union Therapeutics. |
Kenji Kabashima, MD, PhD | Nothing to disclose |
Jonathan I. Silverberg, M.D., Ph.D., M.P.H. | Consulting Fee (e.g., Advisory Board): Abbvie, Alamar, Aldena, Amgen, AObiome, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate Contracted Research: Galderma, Incyte, Pfizer Speakers' Bureau: Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme |
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager | Reported Financial Relationship |
Lindsay Borvansky | Nothing to disclose |
Andrea Funk | Nothing to disclose |
Liddy Knight | Nothing to disclose |
Ashley Cann | Nothing to disclose |
Lauren Sinclair | Nothing to disclose |
Kelly Pechous | Nothing to disclose |
Deborah Sharkey | Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and LiVDerm do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Required Hardware/software
System Requirements
PC Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) | MAC Mozilla Firefox, Apple Safari, Google Chrome For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above) |